Key molecular imaging technology positions Bruker for growth in preclinical PET/MRI and PET/SPECT/CT
BILLERICA, Massachusetts – November 22, 2016 – Bruker today announced that it has completed the acquisition of the preclinical PET imaging business of Oncovision, a leading provider of innovative medical imaging devices. Bruker had previously announced an agreement to acquire this business in September 2016. Financial terms were not disclosed.
The recently introduced, next-generation AlbiraSi™ preclinical PET/SPECT/CT system features advanced silicon photomultiplier (SiPM) technology. This proprietary detector technology allows the highest full field-of-view PET resolution and sensitivity, a major advantage over traditional PET technology. This innovation has also allowed the development of the first SiPM-based PET insert for preclinical MRI systems, giving researchers the benefit of simultaneous PET and MRI measurements.
Dr. Wulf I. Jung, President of Bruker’s Preclinical Imaging Division, stated: “PET imaging is one of the most important imaging modalities for translational research. With this acquisition Bruker is strengthening its leadership in preclinical imaging. The unique, performance-leading SiPM PET detector technology, and other PET capabilities developed in close collaboration with the molecular imaging institute I3M and the University of Valencia, offer outstanding spatial resolution across the full field of view (FOV), increasing the high-resolution FOV by an order of magnitude compared to traditional PET systems, and thereby facilitating quantitative imaging investigations.”
Frank H. Laukien, Ph.D., President and CEO of Bruker Corporation, commented: “Bruker continues to invest and position itself for sustainable growth in the important preclinial imaging market. We are very pleased with this advanced technology acquisition, and believe that our unique PET/MRI and PET/SPECT/CT systems will significantly advance quantitative, highest resolution PET translational research.”
About Bruker Corporation (NASDAQ: BRKR)
For more than 50 years, Bruker has enabled scientists to make breakthrough discoveries and develop new applications that improve the quality of human life. Bruker’s high-performance scientific research instruments and high-value analytical solutions enable scientists to explore life and materials at molecular, cellular and microscopic levels.
In close cooperation with our customers, Bruker is enabling innovation, productivity and customer success in life science molecular research, in applied and pharma applications, in microscopy, nano-analysis and industrial applications, as well as in cell biology, preclinical imaging, clinical research, microbiology and molecular diagnostics. For more information: www.bruker.com/preclinicalimaging
Head of Investor Relations
T: +1 (978) 663 3660, ext. 1479
Dr. Thorsten Thiel
Head of Group Marketing
Tel: +49 (0)721 5161, ext. 6500